Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas

To investigate the safety and efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy for up to 12 months in women with heavy menstrual bleeding associated with uterine leiomyomas. METHODS: Elaris UF-EXTEND was a phase 3 extension study that evaluated...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Obstet Gynecol
Päätekijät: Simon, James A., Al-Hendy, Ayman, Archer, David F., Barnhart, Kurt T., Bradley, Linda D., Carr, Bruce R., Dayspring, Thomas, Feinberg, Eve C., Gillispie, Veronica, Hurtado, Sandra, Kim, JinHee, Liu, Ran, Owens, Charlotte D., Muneyyirci-Delale, Ozgul, Wang, Alice, Watts, Nelson B., Schlaff, William D.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Lippincott Williams & Wilkins 2020
Aiheet:
Contents
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7253187/
https://ncbi.nlm.nih.gov/pubmed/32459423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/AOG.0000000000003869
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia